May 08, 2017
The Lancet Oncology: Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Learn More >>

October 12, 2016
PLOS ONE: A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma
Learn More >>

October 15, 2014
Clinical Cancer Research: A Phase I Study of the First-in-Class Antimitochondrial
Metabolism Agent, CPI-613, in Patients with Advanced
Hematologic Malignancies
Learn More >>

October 04, 2014
Taylor & Francis: Lipoic acid and lipoic acid analogs in cancer metabolism and chemotherapy
Learn More >>

March 10, 2014
Cancer and Metabolism: A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process
Learn More >>

July 19, 2011
Journal of Molecular Medicine: Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo
Learn More >>

Publications

May 08, 2017
The Lancet Oncology: Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Learn More >>

October 12, 2016
PLOS ONE: A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma
Learn More >>

October 15, 2014
Clinical Cancer Research: A Phase I Study of the First-in-Class Antimitochondrial
Metabolism Agent, CPI-613, in Patients with Advanced
Hematologic Malignancies
Learn More >>

October 04, 2014
Taylor & Francis: Lipoic acid and lipoic acid analogs in cancer metabolism and chemotherapy
Learn More >>

March 10, 2014
Cancer and Metabolism: A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process
Learn More >>

July 19, 2011
Journal of Molecular Medicine: Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo
Learn More >>